Thrombolysis in Intermediate-Risk Pulmonary Embolism Who Should Receive Early Reperfusion Review Abstract Background Intermediate-risk pulmonary embolism sits in a genuinely difficult therapeutic space. On one side, you have uncomplicated pulmonary embolism managed primarily with anticoagulation. On the other side, pulmonary embolism complicated by cardiopulmonary failure that demands urgent
Tag: Anticoagulation
Device-Detected Subclinical Atrial Fibrillation in the Wearable Era: When Is Anticoagulation Justified?
Device-Detected Subclinical Atrial Fibrillation in the Wearable Era: When Is Anticoagulation Justified? Review Abstract Background Consumer wearables, ambulatory electrocardiographic monitors, pacemakers, implantable cardioverter-defibrillators, and implantable cardiac monitors are increasingly identifying brief and asymptomatic atrial arrhythmias. However, a photoplethysmography-based irregular-rhythm notification is not equivalent to a diagnosis
Thrombosis and Cancer Immunotherapy: The Next Frontier of Thromboinflammation
Thrombosis and Cancer Immunotherapy The Next Frontier of Thromboinflammation Review Abstract Cancer immunotherapy has fundamentally transformed the treatment landscape across multiple malignancies, offering durable responses and prolonged survival in patients with previously limited therapeutic options. Immune checkpoint inhibitors, chimeric antigen receptor T cell therapies, bispecific antibodies,
Controversies in Antiphospholipid Syndrome: DOACs vs. Warfarin
Controversies in Antiphospholipid Syndrome: DOACs vs. Warfarin Check out our extensive video library (see channel for our latest videos) Abstract Antiphospholipid syndrome (APS) represents a complex autoimmune disorder characterized by thrombotic events and pregnancy complications in patients with persistent antiphospholipid antibodies. The traditional anticoagulant
Anticoagulation Therapy In Risky Geriatric Cardiac Patients
Anticoagulation Therapy In Risky Geriatric Cardiac Patients In the realm of cardiovascular health, the coexistence of atrial fibrillation (AF) with heart failure (HF) presents a significant challenge for anticoagulation, particularly in the aging population. Uncertainties abound regarding treatment efficacy and patient outcomes. The All Nippon AF In the Elderly (ANAFIE) Registry,
